Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • breast cancer

    Tag: breast cancer

    You Searched For "breast-cancer"
    With DCGI Nod in hand, Roche launches Breast Cancer Drug Atezolizumab in India

    With DCGI Nod in hand, Roche launches Breast Cancer Drug Atezolizumab in India

    Medical Dialogues Bureau9 April 2020 7:00 AM GMT
    New Delhi: Drug firm Roche India on Wednesday said it has launched immunotherapy drug Atezolizumab for the treatment of metastatic triple-negative...
    Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list

    Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list

    Medical Dialogues Bureau29 Nov 2019 3:45 AM GMT
    Seventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab,...
    OncoStem Diagnostics named

    OncoStem Diagnostics named 'Best Innovation- Cancer Risk Assessment' by NASSCOM Life sciences and healthcare innovation forum

    Medical Dialogues Bureau29 Sep 2019 4:27 AM GMT
    Bangalore, : OncoStem Diagnostics, an Oncology focused company that enables personalised cancer treatment was named as 'Best Innovation- Cancer Risk...
    Mylan launches generic version of Faslodex Injection to treat breast cancer

    Mylan launches generic version of Faslodex Injection to treat breast cancer

    Medical Dialogues Bureau19 Sep 2019 4:05 AM GMT
    New Delhi: Mylan N.V. recently announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic...
    Allergan announces worldwide recall of textured breast implant tied to rare cancer

    Allergan announces worldwide recall of textured breast implant tied to rare cancer

    Medical Dialogues Bureau26 July 2019 3:45 AM GMT
    The U.S. Food and Drug Administration said it called for the removal after new information showed Allergan Inc's Biocell breast implants account for a...
    Novartis wins USFDA approval for first PI3K inhibitor for breast cancer

    Novartis wins USFDA approval for first PI3K inhibitor for breast cancer

    Farhat Nasim27 May 2019 12:40 PM GMT
    The drug, alpelisib, to be marketed under the brand name Piqray, belongs to a class of drugs known as PI3K inhibitors and is the first of its kind to...
    AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise

    AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise

    Medical Dialogues Bureau10 May 2019 3:30 AM GMT
    The treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
    AstraZeneca ties up with Transgene to develop viral immunotherapies

    AstraZeneca ties up with Transgene to develop viral immunotherapies

    Garima2 May 2019 3:55 AM GMT
    AstraZeneca has been moving deeper into cancer therapy market through wide-ranging deals, including those for immunotherapy and targeted therapy.New...
    Pfizer gets CHMP opinion for Talzenna for patients with metastatic breast cancer

    Pfizer gets CHMP opinion for Talzenna for patients with metastatic breast cancer

    Farhat Nasim29 April 2019 4:05 AM GMT
    The positive CHMP opinion of TALZENNA follows the medicine's approval by the U.S. Food and Drug Administration (FDA) in October 2018.New Delhi:...
    Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate

    Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate

    Meghna A Singhania11 April 2019 5:20 AM GMT
    Mumbai: In a move that will provide relief to cancer patients, drugmaker Intas Pharmaceuticals has recently announced the launch of Trastuzumab...
    Emcure launches generic Eribulin at 40 percent lower price in India

    Emcure launches generic Eribulin at 40 percent lower price in India

    Farhat Nasim4 April 2019 4:00 AM GMT
    Emcure Pharmaceuticals will manufacture Eribulin at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent...
    AstraZeneca, Daiichi Sankyo sign $6.9 billion cancer drug deal

    AstraZeneca, Daiichi Sankyo sign $6.9 billion cancer drug deal

    Garima29 March 2019 3:45 AM GMT
    Under the deal, AstraZeneca will pay Daiichi up to $6.9 billion, including a $1.35 billion upfront payment. The two companies will share development...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X